Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Fátima Cardoso, A. Costa, Larry Norton, et al.
Annals of Oncology (2014) Vol. 25, Iss. 10, pp. 1871-1888
Open Access | Times Cited: 509

Showing 1-25 of 509 citing articles:

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, et al.
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 11, pp. 674-690
Open Access | Times Cited: 2359
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus, et al.
Annals of Oncology (2016) Vol. 28, Iss. 1, pp. 16-33
Open Access | Times Cited: 1927
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge, Masakazu Toi, Patrick Neven, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 25, pp. 2875-2884
Closed Access | Times Cited: 1370
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso, Shani Paluch‐Shimon, Elżbieta Senkus, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1623-1649
Open Access | Times Cited: 1075
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso, Elżbieta Senkus, A. Costa, et al.
Annals of Oncology (2018) Vol. 29, Iss. 8, pp. 1634-1657
Open Access | Times Cited: 1055
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1475-1495
Open Access | Times Cited: 834
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Véronique Dièras, David Miles, Sunil Verma, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 6, pp. 732-742
Open Access | Times Cited: 556
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
J.F.R. Robertson, Igor Bondarenko, Ekaterina Trishkina, et al.
The Lancet (2016) Vol. 388, Iss. 10063, pp. 2997-3005
Open Access | Times Cited: 520
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga, Seock‐Ah Im, Hiroji Iwata, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 7, pp. 904-916
Open Access | Times Cited: 499
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
Michael J. Duffy, Nadia Harbeck, M. Nap, et al.
European Journal of Cancer (2017) Vol. 75, pp. 284-298
Open Access | Times Cited: 453
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts, Catarina Xavier, Johannes Heemskerk, et al.
Journal of Nuclear Medicine (2015) Vol. 57, Iss. 1, pp. 27-33
Open Access | Times Cited: 379
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Edith A. Perez, Carlos H. Barrios, W. Eiermann, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 2, pp. 141-148
Open Access | Times Cited: 376
SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer
Bruno V. Sinn, Chunxiao Fu, Rosanna Lau, et al.
npj Breast Cancer (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 328
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 19, pp. 2141-2148
Open Access | Times Cited: 327
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Fátima Cardoso, John M.S. Bartlett, Leen Slaets, et al.
Annals of Oncology (2017) Vol. 29, Iss. 2, pp. 405-417
Open Access | Times Cited: 324
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana, et al.
Annals of Oncology (2015) Vol. 27, Iss. 4, pp. 619-624
Open Access | Times Cited: 314
Brain Metastases in Newly Diagnosed Breast Cancer
Allison Martin, Daniel Cagney, Paul J. Catalano, et al.
JAMA Oncology (2017) Vol. 3, Iss. 8, pp. 1069-1069
Open Access | Times Cited: 262
Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015)
Fátima Cardoso, Danielle Spence, Shirley Mertz, et al.
The Breast (2018) Vol. 39, pp. 131-138
Closed Access | Times Cited: 241
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Matthew J. Ellis, Antonio Llombart‐Cussac, David Feltl, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 32, pp. 3781-3787
Open Access | Times Cited: 222
Second international consensus guidelines for breast cancer in young women (BCY2)
Shani Paluch‐Shimon, Olivia Pagani, Ann H. Partridge, et al.
The Breast (2016) Vol. 26, pp. 87-99
Open Access | Times Cited: 221
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, et al.
The Oncologist (2016) Vol. 21, Iss. 10, pp. 1165-1175
Open Access | Times Cited: 215
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, et al.
Cancer Research (2017) Vol. 77, Iss. 9, pp. 2213-2221
Open Access | Times Cited: 215
A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer
Wee Loon Ong, Maartje G. Schouwenburg, A.C.M. van Bommel, et al.
JAMA Oncology (2016) Vol. 3, Iss. 5, pp. 677-677
Closed Access | Times Cited: 202
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Marc C. Chamberlain, Christina S. Baik, Vijayakrishna K. Gadi, et al.
Neuro-Oncology (2016) Vol. 19, Iss. 1, pp. i1-i24
Open Access | Times Cited: 201
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Nandini Dey, Pradip De, Brian Leyland‐Jones
Pharmacology & Therapeutics (2017) Vol. 175, pp. 91-106
Closed Access | Times Cited: 196
Page 1 - Next Page

Scroll to top